Hodgkin lymphoma

lymphoma that is marked classically by the presence of Reed-Sternberg cells

British pathologist and social reformer (1798-1866)

cell type associated with Hodgkin lymphoma

ABVD is a chemotherapy regimen used in the first-line treatment of Hodgkin lymphoma, replacing the older MOPP protocol. It consists of concurrent treatment with the chemotherapy drugs: Adriamycin (also known as doxorubicin/hydroxydaunorubicin, designated as H in CHOP) Bleomycin Vinblastine Dacarbazine (similar to procarbazine, designated as P in MOPP and in COPP)

BEACOPP is a chemotherapy regimen for treatment of Hodgkin lymphoma developed by the German Hodgkin Study Group used for patients in Stages > II or early (IA or IB) with unfavorable risk factors. Patients typically receive treatment in cycles of 21 days with no drugs given on days 15–21. There also exists a more intensive regimen with cycles of 14 days. Usually a course of BEACOPP therapy consists of four, sometimes six to eight cycles, or in combination with ABVD. In some countries BEACOPP still is experimental, in others (e.g. Germany and Austria) it is a standard therapy. In the United Stat

chemotherapy regimen